UroGen Pharma Ltd. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- UroGen Pharma Ltd. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $31.83M.
- UroGen Pharma Ltd. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $7.97M, a 46.88% decline year-over-year.
- UroGen Pharma Ltd. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $3.13M, a 94.28% decline year-over-year.
- UroGen Pharma Ltd. stock issued during period, value, new issues for fiscal 2025 was $42.93M, a 71.60% decline from fiscal 2024.
- UroGen Pharma Ltd. stock issued during period, value, new issues for fiscal 2024 was $151.17M, a 124.43% increase from fiscal 2023.
- UroGen Pharma Ltd. stock issued during period, value, new issues for fiscal 2023 was $67.36M.
- UroGen Pharma Ltd. stock issued during period, value, new issues for fiscal 2020 was $15.78M, a 90.23% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $31.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $42.93M 10-K · filed 2026-03-02 |
| 2025-09-30 | $7.97M 10-Q · filed 2025-11-06 | $11.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $18.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.13M 10-Q · filed 2026-05-06 | $99.64M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $151.17M 10-K · filed 2026-03-02 |
| 2024-09-30 | $15.00M 10-Q · filed 2025-11-06 | $151.17M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $81.51M 10-Q · filed 2025-08-07 | $203.52M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $54.66M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $67.36M 10-K · filed 2025-03-10 |
| 2023-09-30 | $67.36M 10-Q · filed 2024-11-06 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $15.78M 10-K · filed 2022-03-21 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2020-06-30 | $15.78M 10-Q · filed 2021-08-04 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $161.45M 10-K · filed 2021-03-18 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $161.45M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $161.45M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $161.45M 10-Q · filed 2020-05-07 | $161.45M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $64.19M 10-K · filed 2019-02-28 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | |
| 2018-03-31 | $64.19M 10-Q · filed 2019-05-09 | |
| 2015-12-31 | $21.25M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |